High-Content siRNA Screen Reveals Global ENaC Regulators and Potential Cystic Fibrosis Therapy Targets  by Almaça, Joana et al.
ResourceHigh-Content siRNA Screen Reveals
Global ENaC Regulators and Potential
Cystic Fibrosis Therapy Targets
Joana Almac¸a,1,5 Diana Faria,1,2,5 Marisa Sousa,1 Inna Uliyakina,1 Christian Conrad,3 Lalida Sirianant,2 Luka A. Clarke,1
Jose´ Paulo Martins,4 Miguel Santos,4 Jean-Karim Heriche´,3 Wolfgang Huber,3 Rainer Schreiber,2 Rainer Pepperkok,3
Karl Kunzelmann,2 and Margarida D. Amaral1,*
1University of Lisboa, Faculty of Sciences, BioFIG - Centre for Biodiversity, Functional and Integrative Genomics, Campo Grande, C8 bdg,
1749-016 Lisboa, Portugal
2Department of Physiology, University of Regensburg, 93053 Regensburg, Germany
3Cell Biology/Biophysics Unit, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany
4EcBio - R&D in Biotechnology SA, 2700-451 Amadora, Portugal
5These authors contributed equally to this work
*Correspondence: mdamaral@fc.ul.pt
http://dx.doi.org/10.1016/j.cell.2013.08.045SUMMARY
Dysfunction of ENaC, the epithelial sodium channel
that regulates salt and water reabsorption in
epithelia, causes several human diseases, including
cystic fibrosis (CF). To develop a global under-
standing of molecular regulators of ENaC traffic/
function and to identify of candidate CF drug targets,
we performed a large-scale screen combining high-
content live-cell microscopy and siRNAs in human
airway epithelial cells. Screening over 6,000 genes
identified over 1,500 candidates, evenly divided be-
tween channel inhibitors and activators. Genes in
the phosphatidylinositol pathway were enriched on
the primary candidate list, and these, along with
other ENaC activators, were examined further with
secondary siRNA validation. Subsequent detailed
investigation revealed ciliary neurotrophic factor re-
ceptor (CNTFR) as an ENaC modulator and showed
that inhibition of (diacylglycerol kinase, iota) DGKi,
a protein involved in PiP2 metabolism, downgrades
ENaC activity, leading to normalization of both Na+
and fluid absorption in CF airways to non-CF levels
in primary human lung cells from CF patients.INTRODUCTION
ENaC, the epithelial sodium (Na+) channel is amajor player in salt
and water reabsorption and epithelial surface hydration in a
number of tissues, including airways and alveolar sacs, ducts
of exocrine glands, renal collecting duct, and distal colon.
ENaC plays a prominent role in lung liquid clearance by the alve-
olar epithelium after birth by reabsorbing fetal lung fluid (O’Bro-
dovich, 1991).1390 Cell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc.As a member of the degenerin ion channel family, ENaC con-
sists of three main subunits, a-, b- and g-ENaC (Canessa et al.,
1994). ENaC impairment leads to diverse diseases with the hall-
mark of local or systemic imbalance in Na+ and water homeosta-
sis. ENaC loss-of-function results for example in renal salt
wasting (type I pseudohypoaldosteronism) or pulmonary edema
(Berthiaume andMatthay, 2007). In contrast, ENaC gain-of-func-
tion leads to several forms of salt-sensitive hypertension (e.g.,
Liddle syndrome) or cystic fibrosis (CF) (Bonny and Hummler,
2000; Lifton et al., 2001; Donaldson and Boucher, 2007).
CF is a life-threatening disease caused by mutations in the
gene encoding the CF transmembrane conductance regulator
(CFTR) protein, a chloride (Cl) channel localized in the apical
membrane of epithelial cells (Riordan, 2008). Physiologically,
CFTR inhibits ENaC and thus regulates pulmonary Na+ absorp-
tion (Kunzelmann et al., 1995; Gentzsch et al., 2010). In CF, how-
ever, the absence of active CFTR leads to Na+ hyperabsorption,
which causes dehydration of airway surface liquid (ASL), a hall-
mark of CF (Boucher, 2007; Mall et al., 1998). Compelling evi-
dence for the major role that ENaC plays in CF airways came
from ßENaC-overexpressing mice, which mimic various aspects
of human CF respiratory disease (Mall et al., 2004). This is in
striking contrast to CFTR knockout or CFTR mutant mice, which
do not develop lung disease (Snouwaert et al., 1992).
Membrane levels of ENaC are mostly regulated by endocy-
tosis and proteolysis mediated by the E3-ubiquitin-ligase
Nedd4-2. Another mouse model, a lung-specific Nedd4-2
knockout, was shown to also develop a CF-like condition
(Kimura et al., 2011), further establishing the key role of ENaC
in CF airway disease.
So, along with the search for small molecules to restore CFTR
activity, ENaC inhibitors have been sought for CF therapeutics to
reduce ENaC-mediated Na+ hyperabsorption and increase ASL
hydration (Amaral and Kunzelmann, 2007). Such a goal might
also be of interest to treat chronic obstructive lung disease
(COPD), disseminated bronchiectasis, or even CFTR dysfunc-
tion caused by cigarette smoking (Clunes et al., 2012). ENaC
Figure 1. ENaC Functional Screening Assay
(A) Images of A549 cells subjected to the FMP/
Amil assays before (left) and after Amil (right). Cells
grown for 48 hr under dexamethasone (+Dexa,
top) demonstrated enhanced FMP/Amil quench-
ing (higher ENaC activity) than cells grown in the
absence of Dexa (bottom).
(B) Quantification of the Amil-sensitive FMP fluo-
rescence of images in A shows greater ENaC
activity in cells grown under Dexa.
(C) Images of A549 cells grown for 48 hr under
Scrbld, aENaC, or ßCOP siRNAs.
(D) Summary of the median ratio Amil-sensitive
FMP fluorescence ratios for all spots in the same
slide (‘‘slide’’), scrambled (‘‘Scrbld’’), aENaC and
ßCOP siRNA spots. Average of Amil-sensitive ra-
tios (n = 5) is shown as a red line ± SD.blockers may also serve to hydrate mucosal surfaces of the
gastrointestinal tract, mouth, nose, and eye and treat ENaC
gain-of-function conditions, like ENaC-related hypertension
(Butterworth et al., 2009). Amiloride (Amil), used for the manage-
ment of hypertension and congestive heart failure, was the first
ENaC pharmacological inhibitor tested in CF, but studies
showed no significant improvement due to its short half-life in
the lungs (Knowles et al., 1990). Longer-acting and more potent
ENaC inhibitors (IC50 10 nM) include Amil derivatives such as
benzamil or PS552 (Parion Sciences, Durham, NC), both yielding
disappointing results in CF trials (Donaldson and Boucher, 2007;
Hirsh et al., 2006). Excessive blocking of ENaC may cause
severe harm, via undesirable accumulation of fluid in the lungs,
i.e., pulmonary edema (Althaus et al., 2011). Instead, we need
compounds normalizing ASL homeostasis through physiological
regulation of ENaC. If achieved independently of CFTR, such
normalization could correct ion transport in CF patients with
any CFTR mutation.
Despite detailed knowledge on how several ENaC regulators
control both channel number at the cell surface and its open
probability (Butterworth et al., 2009), many aspects of ENaC
biogenesis, trafficking, and regulation remain obscure. Herein,
we have undertaken a large-scale loss-of-function (siRNA)
screen for ENaC with the ultimate goal of identifying putative
druggable targets. We used a live-cell assay and automatic
microscopy to functionally assess ENaC in human respiratory
epithelial cells after reverse siRNA transfection (Erfle et al.,
2007) with libraries targeting a total of 6,396 genes. We thus
identified 1,626 genes regulating ENaC: 887 inhibitors and 739
activators. Bioinformatic analyses of primary hits identified the
phosphatidylinositol (PI) pathway as the top enriched pathway
(with 30 hits), 37% of which were validated. The top 60%
primary ENaC-hits also underwent reassessment, achieving
30% validation.Cell 154, 1390–1400, SepThe validated hits were then classified
into known ENaC regulatory pathways.
Seven genes were found to lie outside
such pathways and 2 of these were cho-
sen for further investigation and shown to
be key ENaC regulators: diacylglycerolkinase iota (DGKi), a potential robust CF therapeutic target;
and ciliary neurotrophic factor receptor (CNTFR), an original
ENaC modulator, which proved the screen’s power to identify
novel hits.
RESULTS
Live-Cell siRNA Screen Identifies 1,626 ENaC
Regulators
For the high-content siRNA screen, we used a live-cell assay
measuring ENaC activity through the voltage-sensitive fluores-
cent FMP dye in combination with specific ENaC blocker Amil
(Almac¸a et al., 2011). Human alveolar epithelial cells A549
(with endogenous ENaC expression) were grown under dexa-
methasone (Dexa) to maximize ENaC expression (Figures 1A
and 1B) (Itani et al., 2002). Cells were transfected with siRNAs
targeting a-ENaC subunit or ßCOP (component of traffic vesi-
cles) as positive controls and scrambled siRNA (Scrbld) as nega-
tive control. As expected both a-ENaC and ßCOP siRNAs (but
not Scrbld) significantly suppressed the quenching of Amil-
induced fluorescence (Figures 1C and 1D). The difference
between the values for positive (si-aENaC/ si-ßCOP) and Scrbld
or ‘‘slide score’’ (see Supplemental Information) is relatively
modest (10%). However, due to high reproducibility and lack
of overlap between positive and negative controls (Figure 1D)
we could proceed to high-content microscopy screening.
Indeed, the robustness of the microscopy approach and image
analysis, allowing collection of cell-based multi-information
data (number of cells, removal of debris, apoptotic cells, etc.),
enabled quality control, which, together with ‘‘local background’’
correction and robust statistics (Chung et al., 2008) led to reliable
and reproducible hit discrimination.
For the automated high-throughput microscopy screen, we
individually silenced 6,396 protein-coding human genes, usingtember 12, 2013 ª2013 Elsevier Inc. 1391
Figure 2. Overview of Screen Data
(A) Distribution of averaged ‘‘SNS-score’’ values
obtained for every siRNA in the primary screen.
The ‘‘SNS-scores’’ calculated for each siRNA spot
and averaged among replicates were used to
assess how each siRNA affected ENaC activity.
siRNAs with SNS-scores R 2 or % 2 (black
dashed horizontal lines) were considered as ENaC
activators or inhibitors (yellow shade) siRNAs,
respectively. See also Figures S1 and S2 and
Datasets S1 and S2.
(B) Scatter plot of data from the validation screen
where each siRNA is represented as the average of
‘‘spot scores’’: blue,‘‘empty spots’’ (i.e., lipofect-
amine with no siRNA); red, Scrbld; green, si-aE-
NaC;orange, si-ßCOP.The thresholdused (red line)
was theminimumnormalized score among ‘‘empty
spots.’’ See also Dataset S3 and Figures S3.
(C) Workflow showing the different steps in the
primary and validation screens and the number of
hit genes after each step.2-3 siRNAs per gene (n = 17,622) and monitored their effects on
ENaC activity by the FMP/Amil assay. The result for each siRNA
consisted in the ‘‘slide-normalized spot score’’ (‘‘SNS-score’’)
averaged from siRNA replicates (Dataset S1A available online).
SNS-scores were put into an ordered distribution (Figure 2A)
and siRNAs with SNS-scores% 2 were considered as inhibit-
ing ENaC (Dataset S1B), whereas those with SNS-scores R 2
were considered as activating ENaC (Dataset S1C, Figure 2A).
In summary (Figure 2C), this primary screen revealed 1,626
hits: 739 genes activating ENaC, i. e., targeted by siRNAs inhib-
iting ENaC (highlighted in yellow in Figure 2C): 711 with one, 27
with two and 1 with 3 siRNAs plus 887 genes inhibiting ENaC,
i.e., targeted by ENaC-activating siRNAs: 832 with one, 52 with
two and 3 with three siRNAs. All 1,626 ENaC regulator hits
were analyzed by DAVID bioinformatic tool for functional annota-
tion, which revealed the phosphatidylinositol (PI) pathway
(KEGG hsa04070) as the most significantly enriched with 30
genes, p < 2x106 (Dataset S2 and Figure S1). After validation
by stringent selection criteria 11 (37%) of these 30 genes could
be established as ‘‘truly confirmed’’ hits with two or more
siRNAs (Dataset S3A and Figure S1): 10 ENaC activators
(CDS1,DGKA,DGKI, ITPK1, ITPR3, PIK3CB, PIK3CD, PIP4K2A,1392 Cell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc.PLCB1, PLCZ1) and 1 ENaC inhibitor
(PIK3C2B). Although other genes among
the 30 had at least two siRNAs that
confirmed the primary screen, they also
had another siRNA with opposite effect
and thus they were not considered as
hits.
As we aimed to identify ENaC activa-
tors (to be inhibited by small molecules),
we also sought for additional siRNA vali-
dation of the top 60% ENaC-activating
genes (456 out of 739 activator genes).
The normalized results of this validation
screen are displayed as a scatter plot in
Figure 2B and siRNAs below the 1
threshold were considered as hits (gray area, Figure 2B). This
is the minimum normalized score for ‘‘empty spots’’ (i.e., posi-
tions with lipofectamine only, no siRNA). We thus confirmed
132 (30%) out of the rescreened 456 primary screen hits (Fig-
ure 2C). These, together with hits targeted by at least two
siRNAs in the primary screen, identified 160 ENaC-activator
genes (Figure 2C, Dataset S3B). As most of these hits encode
proteins never reported as ENaC regulators, we used Gene
Ontology (GO) terms to classify them (Figure S2). We also
checked their role in previous screens using the same siRNAs
or in other relevant studies (Dataset S3B). Interestingly, the
largest group (33%) had been previously implicated in secretory
trafficking (Simpson et al., 2012), followed by 23% in cell division
(Neumann et al., 2010), 5% in plasmamembrane targeting of Src
kinases (Ritzerfeld et al., 2011), and 3% in a global set of CFTR
interactors (Wang et al., 2006). Notably, in the latter group we
found CFTR itself (plus APC, RYK, HSP90B1, COPB1).
Experimental Hit Classification into Known ENaC
Pathways and Further Bioinformatic Analyses
To gain mechanistic insight into how the validated hits regulate
ENaC, we performed the same FMP/Amil assay for these genes
Figure 3. ENaC Pathway Classification of Validated Hits
(A) Validated hits were experimentally classified into known ENaC-regulating
pathways by the same FMP/Amil assay after various treatments (see text).
Graph shows mean values of % Amil-sensitive ratio ± SD (n = 16 spots).
(B) Heat maps showing normalized scores for siRNAs targeting the validated
hits and their sensitivity to various treatments, as indicated. Score values
range from 5 (green, inhibitory siRNA) to +5 (red, activatory siRNA).
See also Figure S4 and Datasets S4 and S5.under conditions that interfere with pathways known to affect
ENaC, namely: (1) incubation of cells with protease inhibitor
aprotinin to inhibit ENaC activation by proteolytic cleavage (Gail-
lard et al., 2010) by; (2) under Nedd4-2 siRNA transfection to
inhibit ENaC endocytosis mediated by the Nedd4-2/SGK1
pathway (Staub et al., 1997; Debonneville et al., 2001); and (3)
after induction of WT- (or F508del-) CFTR expression in trans-
duced A549 cells to inhibit (or not) ENaC (Kunzelmann et al.,
1995; Almac¸a et al., 2011).
Data in Figure 3A (left graph) show first that aprotinin-treated
cells exhibit a modest but consistent and significant decrease
(20%) in the Amil-sensitive ratio versus control cells, as
expected due to inhibition of ENaC activation by serine endo-
peptidases. Second, data show (Figure 3A, left) that removal of
Dexa (6h) already causes significant ENaC inhibition, which,
however, can be reverted by Nedd4-2 siRNA with a significant
15% increase versus control cells. Third, induction of WT-
CFTR expression (but not of F508del-CFTR) by doxycycline
and butyrate (Dox/but), causes a significant decrease in ENaC
function of 50% (Figure 3A, right graph). By recapitulating theCin vivo regulation of ENaC by CFTR (Kunzelmann et al., 1995),
these cells are thus very useful to test how the novel ENaC
regulators relate to CFTR.
Next, by rescreening the validated ENaC activators under
these 3 conditions we classified them according to such path-
ways (heat-maps in Figure 3B). For example, under Nedd4-2
downregulation, 56% of the siRNA hits no longer inhibited
ENaC (‘‘Nedd4-2-sensitive’’ hits) suggesting that they exert their
effects on this pathway and indicating the central role that
this E3-ubiquitin ligase plays on ENaC regulation. Also, in the
presence of aprotinin,32%of the siRNA hits no longer inhibited
ENaC, suggesting that their effects on ENaC are protease-
mediated.
Based on their sensitivity to these treatments, the validated
hits were grouped into 5 different classes (Figure 3B and Dataset
S4): (1) class I (23%) insensitive to all treatments; (2) class II
(18%) sensitive to all three treatments; (3) class III, (4) class
IV, (5) class V, hits sensitive only to aprotinin (3%), 6h-Dexa
(13%) or Nedd4-2-siRNA (23%), respectively. Additional
sets (classes VI, VII and VIII) include hits that are sensitive to
two out of the three treatments (Dataset S4). Classification of
hits according to their CFTR-dependence produced additional
classes (marked ‘‘*,’’Dataset S4). For example, class IV* includes
hits no longer affecting ENaC upon WT-CFTR expression. Of
particularly interest are hits showing differential effects in the
presence of WT- versus F508del-CFTR (classes IV* and V*) as
they may be key to elucidate how WT-CFTR (but not
F508del-CFTR) prevents ENaC-mediated Na+ hyperabsorption
in non-CF individuals. Seven hits were insensitive to all treat-
ments (classes ‘‘I and I*’’) namely: ACY3; CCNI; CNTFR; DGKi;
IQCF1;MEST; SERPINB3. As they fall out of known ENaC regu-
latory pathways they deserve further investigation.
To select for putative drug targets and learn more about the
validated genes, additional bioinformatic analyses were per-
formed, including a measure of their ‘‘closeness to ENaC,’’ given
by ‘‘cosine similarity’’ values (see Supplemental Information).
This was based on the proteases-Nedd4-2 scores (Dataset
S4B) and used as reference values for si-aENaC: the higher
the cosine similarity the closer genes are to ENaC (Dataset S5
and Figure S3). We also submitted the above 7 ‘‘insensitive’’
hits to predictive protein-protein functional correlations (FunL,
see Supplemental Information) in relation to ENaC. From the
resulting network (Figure S4) two genes emerged functionally
closer to ENaC: CNTFR and DGKi. We next selected both genes
for further studies.
Although DGKwas a recognized ENaC regulator (Kunzelmann
et al., 2005), its DGKi isoform was mechanistically evaluated
here as a possible drug target for CF. Indeed, four main reasons
led to selection of DGKi: first, DGKi emerged as a key hit in the
top-enriched pathway—the PI signaling system (Figure S1 and
Dataset S2); second, the DGKi isoform was found to be highly
expressed in human airways (Figure S5); third, bioinformatic
analysis (Figure S3) ranked DGKi very close to ENaC (nr.11)
even higher than CFTR (nr.14); finally, as a kinase, it is amenable
to small-molecule inhibition and thus a good drug target. CNTFR
in turn, was also further investigated as an original hit due to its
bioinformatic proximity to ENaC (Figures S3 and S4) and to





Figure 4. Regulation of ENaC by DGK
(A) Recordings of voltage-dependent FMP fluorescence in individual A549
cells demonstrate fluorescence decrease after application of Amil, due to
hyperpolarization of the membrane voltage.
(B) Summary of data shows inhibition of Amil-induced quenching in A549 cells
after inhibition of DGK (DGKinh, 25 mM).
(C) Original Ussing chamber recordings of transepithelial voltages (Vte)
assessed in mouse trachea before and after treatment with DGKinh (25 mM, 1-2
h; n = 13).
(D) Summary of Ieq-Amil in mouse trachea demonstrating inhibition of ENaC by
DGKinh.
(E) Summary of the effects of DGKinh on ENaC activity measured as Amil-
sensitive conductances (GAmil) in Xenopus oocytes expressing WT-abgENaC,
truncated aH648XbgENaC, or abDNg-ENaC lacking an N-terminal PIP2-inter-
action domain in b-subunit (abDNg-ENaC) (each n = 12).
(F) FMP assay on A549 cells treated with either with Scrbld or si-DGKi-siRNA.
Cells were incubated for 2–5 hr with compounds inhibiting PLC (U73122;
20 mM) or activating PLC (m3M3FBS; 25 mM), inhibiting PI3K (LY294002;
10 mM) or activating PKC (PMA; 10 mM).
Mean ± SEM. #, significant difference versus controls (unpaired t test and
ANOVA; p < 0.05). See also Figure S5.DGKi: a Robust Therapeutic Target for ENaC
DGKiwas thus investigated as a drug target candidate for ENaC
regulation and results in various cell types showed that it is
essential for maintenance of ENaC activity. First, we showed
that a chemical blocker of DGK (DGKinh, 25 mM) led to 50%
ENaC inhibition in A549 cells (Figures 4A and 4B). Second, in1394 Cell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc.mouse tracheas assessed ex vivo in Ussing chambers, DGKinh
attenuated Amil-induced voltage deflection and inhibited Amil-
sensitive short-circuit current, indicating inhibition of ENaC by
60% (Figures 4C and 4D). Third, these data were confirmed
in polarized H441 human airway epithelial cells and M1 mouse
collecting duct cells (data not shown), as well as after coex-
pression of three ENaC subunits (abg) in Xenopus oocytes,
where the Amil-inhibited whole-cell conductance (GAmil) was
30% inhibited by DGKinh (Figure 4E, left bar).
To better understand the underlying mechanisms, we
assessed ENaC conductance in Xenopus oocytes, by coex-
pressing DGKi and WT- or truncated (aH648X) aENaC with WT-
bgENaC. We found that 60% of GAmil produced by aH648X
bgENaC was inhibited by DGKinh, in contrast to only 30% for
abgENaC (Figure 4E). The truncated aH648X lacks an essential
binding site for the ubiquitin ligase Nedd4-2, resulting in
enhanced ENaC-activity (GAmil = 107.27 ± 26.4 versus 47.25 ±
4.8 mS) that is fully subjected to regulation by PIP2 and DGKinh
(Yue et al., 2002; Kunzelmann et al., 2005). The inhibitory effect
of DGKi-siRNA on ENaC was therefore augmented because-
Nedd4-2-dependent regulation is largely reduced for aH648X
bgENaC. In contrast, deletion of the N terminus of b-ENaC
largely inhibited ENaC conductance (GAmil = 1.4 ± 0.5 mS) and
only 20% of the remaining conductance was inhibited by
DGKinh (Figure 4E, right bar). Because binding of N terminus of
b-ENaC to PIP2 is essential to maintain ENaC activity (Pochy-
nyuk et al., 2007), these data support the concept that DGK
activates ENaC by maintaining sufficiently high PIP2 levels.
This conclusion was further substantiated by pharmacological
manipulation of enzymes that are crucial for PI metabolism and
ENaC activity, some of which were hits in the primary screen
(Figure S1). Using Amil-sensitive FMP fluorescence in A549 cells
as a measure for ENaC activity, siRNA-DGKi was confirmed to
inhibit by 50% ENaC activity, whereas Scrbld had no effect
(Figure 4F, black versus white bars, respectively). Inhibition of
phospholipase C (PLC) by its blocker U73122, which antago-
nizes hydrolysis of PIP2, completely abrogated the inhibitory
effects of siRNA-DGKi on ENaC (Figure 4F). In contrast, stimula-
tion of PLC by its activator m3M3FBS inhibited ENaC by 40%
and importantly, abolished further inhibition of ENaC by siRNA-
DGKi. These results clearly indicate that DGKi activates ENaC
by maintaining the PIP2 pool in the inner membrane leaflet. The
PiP2 content may also be lowered by phosphatidylinositol-4,5-
biphosphate 3-kinase (PI3K) that converts PIP2 into PIP3 - phos-
phatidylinositol (3,4,5)-trisphosphate (Figure S1). Accordingly,
inhibition of PI3K by its inhibitor LY294002 slightly reduced
ENaC activity because PIP3 is a positive ENaC regulator (Pochy-
nyuk et al., 2007). Notably however, in the presence of the PI3K
inhibitor, siRNA-DGKi no longer inhibited ENaC (Figure 4F), plau-
sibly because of enhanced PIP2 pools. However, PI3K itself is
not a specific target to control ENaC activity because, in contrast
to DGK that is confined to the resynthesis of apical PIP2, PI3K
controls numerous cellular processes (reviewed in Pochynyuk
et al., 2008). DGKi is thus an advantageous target to inhibit
ENaC through PIP2 in the airways because it localizes exclu-
sively to the apical membrane of epithelial cells and in close
proximity to ENaC, where it rather specifically controls apically
located ion channels.
Figure 5. Regulation of ENaC by CNTFR and Effect of mTOR Inhi-
bition by Rapamycin
(A) Summary of the effects of si-CNTFR or mTOR inhibition by rapamycin (or
both together) on ENaC activity, measured by Amil-sensitive FMP fluores-
cence in H441 cells (n = 50 for all series).
(B) Summary of mTOR inhibition by rapamycin on Amil-sensitive Ieq-Amil as
measured in open-circuit Ussing chamber measurements of polarized grown
H441 cells treated with siCNTFR or Scrbld (n = 6–7).
(C) Original recordings of whole-cell currents measured in CNTFR/ENaC co-
expressing oocytes showing enhanced Amil-sensitive Na+ currents after 24 hr
incubation with CNTF (CNTFR ligand).
(D) Summary of effects of CNTF incubation on Amil-sensitive whole-cell
conductances measured in ENaC-expressing Xenopus oocytes (n = 25–29).
(E) Effects mTOR inhibition by rapamycin on Amil-sensitive conductance
(n = 12).
Mean ± SEM. #, different to control; p < 0.05; ANOVA. * indicates significant
inhibition by Amil; p < 0.05; paired t test. See also Figure S6.Notwithstanding, inhibition of DGKi also leads to accumula-
tion of DAG, a potent activator of protein kinase C (PKC), which
is a known inhibitor of ENaC (Stockand et al., 2000). To rule out
that DGKi-dependent activation of ENaC is associated with
DAG-stimulated activation of PKC, we tested the effect of si-
DGKi on ENaC under PKC modulation. As expected, PKC acti-
vation by phorbol 12-myristate 13-acetate (PMA) inhibited
ENaC by 50%. However, siRNA-DGKi further reduced ENaC
activity, suggesting a PKC-independent inhibitory effect (Fig-Cure 4F). These results are supported by data demonstrating
that the PKC-inhibitor bisindolylmaleimide (BIM) is unable to fully
restore ENaC activity in si-DGKi treated cells (data not shown).
Thus, DGKi activates ENaC by regenerating PIP2 pools in the
inner plasma membrane leaflet.
CNTFR: A Novel ENaC Regulator
Before further investigating CNTFR, we assessed its physiolog-
ical relevance in the lung by confirming its expression in human
native airways (Figure S6). Next, CNTFR expression was
knocked-down by siRNA in H441 cells (as confirmed by western
blot, Figure S6) and this attenuated the effects of Amil on FMP
fluorescence (Figure S6C) and inhibited Amil-sensitive transport
(Ieq-Amil) (Figures 5A and 5B). CNTFR couples to several intracel-
lular pathways, one of them being themammalian target of rapa-
mycin (mTOR) (Yokogami et al., 2000). Thus, we next inhibited
mTOR by rapamycin, which also reduced ENaC-mediated Na+
transport (Figure 5B, left). However, rapamycin itself was without
effect on Ieq-Amil after si-CNTFR (Figure 5B, right), suggesting
that CNTFR indeed acts through mTOR. CNTFR effects were
further validated by its overexpression in Xenopus oocytes,
which when coexpressed with ENaC enhanced Amil-sensitive
conductance (Figures 5C and 5D). Notably, 48 hr incubation
of oocytes with the cytokine CNTF (CNTFR ligand) further
increased the Amil-sensitive conductance, whereas inhibition
of mTOR by rapamycin strongly inhibited ENaC (Figure 5E)
(Koehl et al., 2010; Ousingsawat et al., 2008). Thus, CNTF/
CNTFR appears be a novel pathway regulating ENaC operating
through mTOR (Lu et al., 2010). Importantly, ENaC inhibition by
si-CNTFR was also confirmed in primary cultures of HBE cells
from CF patients (Figure S6E).
Validation of DGKi as Drug Target for ENaC in Human CF
Airways
Although the above results clearly demonstrate inhibition of
ENaC by DGKinh, the crucial question is whether this could be
used to inhibit Na+ hyperabsorption in CF airways. We therefore
isolated airway epithelial cells from lungs of CF patients and
grew them as highly differentiated polarized cultures under ALI
conditions. Original Ussing chamber recordings demonstrate
large Amil-induced voltage deflections, indicating pronounced
ENaC activity and Na+ absorption in CF airways (Figures 6A
and 6C). ENaC in CF airways is known to be inhibited by stimu-
lation of apical purinergic P2Y2 receptors, as also shown here by
pronounced attenuation of Amil-induced voltage deflections and
Amil-sensitive transport (Ieq-Amil) after ATP stimulation. When CF
primary cells were treated with DGKinh, Amil-sensitive Na
+
absorption was largely reduced to its physiological levels (Fig-
ures 6B and 6C). Moreover, ATP-stimulation only slightly further
reducedNa+ absorption. Remarkably, in non-CF airway cultures,
Ieq-Amil was lower than in CF airways and DGKinh showed no
significant effects on ion transport. These results indicate that
enhanced Amil-sensitive Na+ absorption is attenuated by DGKinh
to levels found in normal non-CF airways, i.e., restoring Na+
transport homeostasis but not completely blocking it. DGK inhib-
itors are therefore a potentially valuable tool for the treatment of
CF lung disease. Notably DGKinh also delayed transepithelial
fluid absorption in human CF primary epithelial airway cellsell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc. 1395
Figure 6. DGK and CNTFR Inhibit ENaC in Primary CF Airway
Cultures
(A and B) Transepithelial voltages measured in primary CF bronchial epithelial
cells grown in an air liquid interface (ALI) by Ussing chamber. (A) Effects of Amil
(10 mM) and stimulation of apical P2Y receptors by ATP (100 mM); and (B) after
incubation with 25 mM DGKinh for 4–6 hr.
(C) Summary of Amil-sensitive transport (Ieq-Amil) before and after exposure to
DGKinh and inhibition of Ieq-Amil by ATP in CF airways.
(D) Summary of Ieq-Amil and effects of DGKinh and ATP in non-CF airways.
Mean ± SEM; n = 5–7 for non-CF and CF patients, respectively. # indicates
significantly different from control and CF, respectively (p < 0.05, unpaired
t test). *indicates significant effect of Amil (p < 0.05, unpaired t test). See also
Figure S7.and again inhibition was more pronounced in CF versus non-CF
cells (Figures S7A and S7B).
DISCUSSION
The aim of this study was to perform a loss-of-function screen
mainly designed to globally identify regulators of ENaC traffic/
function, with the ultimate goal of finding putative drug targets
for CF. To this end, we used a high-content siRNA screen
whose endpoint was a fluorescent cell-live microscopy assay
measuring ENaC activity on an individual cell basis. Analysis of
the primary screen data led to the identification of 1,626 ENaC
regulators: 739 activator and 887 inhibitor genes. Submission
of the primary hits to bioinformatic annotation showed the phos-
phatidylinositol (PI) signaling system as the most significantly
enriched pathway, represented by 30 genes. Evidence of sup-
pression by the siRNAs was previously shown (Neumann et al.,
2010) by qRT-PCR tests for >97% of the tested transcripts (see
Supplemental Information). Nonetheless, secondary validation
of primary hits, i.e., confirmation with additional siRNAs, is vital.
Because our main goal was to find new ways of inhibiting
ENaC, we focused the hit validation on genes activating ENaC.1396 Cell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc.We thus selected the top 60% (456) genes out of the 739
ENaC activators and on the 30 genes in the PI pathway.Whereas
160 genes were confirmed by at least two independent siRNAs
as ENaC activators in the former group (30%), 11 genes
(37%) from the PI pathway could be validated: ten ENaC activa-
tors and one inhibitor. These validation percentages are within
the range usually found in similar siRNA screens (Neumann
et al., 2010; Simpson et al., 2012). However, this stringent valida-
tion does not completely rule out as ENaC regulators genes that
in the primary screen had an effect but could not be confirmed by
an independent siRNA. Indeed, other siRNAs acting at higher
efficiency may also achieve the effect observed in the primary
screen.
Next, we classified the validated hits in relation to the three
major known pathways regulating ENaC. The obtained hit clas-
sification (Figure 3B and Dataset S4) may be used to generate
multiple hypotheses in various types of analysis. For example,
the genes whose siRNAs are sensitive to all three treatments
(class II) are probably those responsible for the crosstalking
among those three ENaC regulatory pathways. Indeed, the ubiq-
uitination status of ENaC byNedd4-2, for instance, was shown to
affect the proteolytic cleavage of the channel (Ruffieux-Daidie´
et al., 2008), but the mechanism is still unknown. Accordingly,
the nine genes in class VII (Figure 3B), i.e., whose siRNA no
longer inhibit ENaC under aprotinin nor under Nedd4-2-siRNA,
could be related to such crosstalk: KCNQ3, TAS2R1,
TNFRSF1B, B4GALT6, KIFAP3, CDK10, GRINA, SCGB3A1,
and IFIH1 (Dataset S4). One of these (SCGB3A1) is downregu-
lated in CF nasal epithelium (Clarke et al., 2013) and CF bronchial
epithelium (Ogilvie et al., 2011) and upregulated during air-liquid
interface differentiation of human bronchial epithelial cells (Ross
et al., 2007).
Also of particular interest are the 11 validated hits (ADAR;
AKAP14; ARHGEF11; BRD4; DPP9; KIFAP3; MAST3; PIK3CA;
RIPK2; RYK; SCARB2), which no longer inhibited ENaC when
WT-CFTR was expressed, but were insensitive to presence of
F508del mutant (class IV*, Dataset S4). These genes deserve
future examination to elucidate how WT-CFTR (but not
F508del-CFTR) prevents the ENaC-mediated Na+ hyperabsorp-
tion in non-CF individuals. Notably, 4 out of these 11 hits
(AKAP14, KIFAP3, MAST3, and ARHGEF11) are cytoskeleton-
related proteins and ARHGEF11 is a regulator of Rho, which
we recently showed to be critical for the plasma membrane
rescue of F508del-CFTR (Moniz et al., 2013). Interestingly, these
four hits were also found to affect secretory traffic in a previous
screen (Simpson et al., 2012).
Although these hit classes are of interest and deserve further
examination, detailed investigation of all underlyingmechanisms
goes well beyond the present study. Nevertheless, we decided
to focus on original ENaC activators outside the known path-
ways (i.e., hits in classes I and I*) as putative drug targets. Among
the seven genes in these two classes (Dataset S4)—ACY3;
CCNI; CNTFR; DGKi; IQCF1; MEST; and SERPINB3—we
selected two for further mechanistic studies: DGKi as a putative
drug target and CNTFR as a novel ENaC regulator.
Isoform iota of DGKi, never directly described as an ENaC
modulator, was thus further investigated using different ap-
proaches, and results indicate that DGKi supports ENaC activity
Figure 7. Role of DGK and CNTFR on ENaC
Activation
(A) DGK maintains ENaC-activity by regenerating
the PIP2 in the inner leaflet of apical plasma
membrane (I). Activation of P2Y receptors induces
PIP2 hydrolysis, thereby enhancing intracellular
IP3 and Ca
2+. ENaC is inhibited by PKC, which is
activated by DAG and Ca2+, and by lack of ENaC
anchoring to PIP2 via N-terminal lysines (II). Inhi-
bition of DGK depletes themembrane of PIP2, thus
inhibiting ENaC (III).
(B) Binding of CNTF to CNTFR may activate mul-
tiple intracellular pathways, leading to suppres-
sion of Nedd4-2, which increases activity and
membrane expression of ENaC (Koehl et al.,
2010). mTOR upregulates the transcriptional
elongation factor elF4F, which is also in charge of
postnatal upregulation of ENaC due to increase in
O2 partial pressure (Otulakowski et al., 2007).by maintaining PIP2 levels in the inner plasma membrane leaflet.
Indeed, DGKi is a lipid cycle component that is essential for
regeneration of phosphatidylinositols such as PIP2 and our re-
sults support the concept that DGK activates ENaC by regener-
ating the PIP2 pool present in the inner leaflet of the apical
plasma membrane (Figure 7A). Negatively charged phosphoino-
sitides like PIP2 interact with positively charged lysine residues
at the N terminus of b- and g-ENaC, which is necessary to
keep the channel open (Kunzelmann et al., 2005). ATP stimula-
tion of purinergic receptors activates PLC and consequently
PIP2 hydrolysis, which leads to ENaC inhibition (Figure 7B).
Here, we also showed that si-DGKi or its chemical inhibition, re-
duces ENaC activity to 50% in various cell types and mouse
trachea and down to 65% in CF human primary airway cul-Cell 154, 1390–1400, Septures. Notably, attenuation of ENaC by
DGK inhibition was pronounced in CF
airway cultures but was not significant in
non-CF airways. DGK inhibition also
caused a delay in transepithelial fluid
absorption in CF (but not in non-CF)
human primary airway cultures. Impor-
tantly, DGKi inhibition in CF primary
airway cells does not completely block
ENaC activity. Instead, it restores Na+-
absorption to normal levels of non-CF
airways, a condition that should be ful-
filled for potential drugs modulating
ENaC. These data demonstrate the phys-
iological relevance of inhibiting DGKi to
restore ENaC function, Na+ homeostasis,
and fluid absorption. As expression levels
of DGKi in cultured cells parallel those in
native human lung tissues (Figure S5),
DGKi appears a physiologically relevant
potential drug target for CF. When inhibit-
ing DGK in cells even for long periods of
time (up to 72 hr), we did not recognize
any obvious toxicity. Moreover the exclu-sive localization of PIP2 in the apical membrane (Bryant and
Mostov, 2008; Ga´lvez-Santisteban et al., 2012) should limit the
chance for unexpected effects of DGK inhibitors. Interestingly,
this target has been recently proposed to treat inflammation,
coagulation, and cancer (Holden et al., 2011; Marumo et al.,
2012; Filigheddu et al., 2011) with no reported toxicity.
Taken together, inhibition of DGKi, an original regulator of
ENaC activity, seems to constitute a powerful tool to normalize
Na+ absorption and fluid homeostasis in ASL of CF airways.
There is yet an ongoing controversy with respect to Na+ hyper-
absorption as the cause of CF lung disease, particularly in light of
more recent studies on newborn CF pigs, which cast serious
doubt on the concept of hyperabsorption (Chen et al., 2010).
However, studies on human native airways (Boucher et al.,tember 12, 2013 ª2013 Elsevier Inc. 1397
1988; Mall et al., 1998) and ENaC-overexpressing mice (Mall
et al., 2004) still clearly support this concept (recently reviewed
in Kunzelmann and Schreiber, 2012). Despite this controversy,
inhibition of ENaC has been demonstrated in multiple studies
to enhance ASL and to improve mucociliary clearance. Treat-
ment with hypertonic saline, shown to cause ENaC inhibition,
has also been demonstrated to improve mucus clearance and
lung function (Donaldson et al., 2006).
Another significant hit in the present screen, CNTFR, with no
known role in ENaC regulation, was selected to demonstrate
the screen’s potential to identify unexpected ENaC regulators,
and indeed, it was proven to regulate ENaC. Although data
here do not fully explore the intracellular pathways leading to
ENaC activation through CNTFR, they strongly suggest that
CNTFR operates through the mTOR pathway. In fact, earlier
studies inmice with enhancedmTOR activity caused by reduced
expression of the tumor suppressor APC, demonstrated pro-
nounced upregulation of ENaC (Ousingsawat et al., 2008). This
is probably due to upregulation of the transcriptional elongation
factor elF4F, which is also in charge of postnatal ENaC upregu-
lation (Otulakowski et al., 2007).
Taken together, the present results demonstrate the power of
microscopy siRNA screens in discovering novel regulators of ion
channels and drug targets. Detailed studies on two screen hits
regulating ENaC—DGKi and CNTFR—clearly led to original
pathways. Importantly, DGKi seems well-suited as a potential
novel drug target for CF because by its inhibition ENaC activity
is reduced, and both Na+ and fluid absorption are normalized
in CF airways to non-CF levels.
EXPERIMENTAL PROCEDURES
Materials
The FMP/Amil live-cell assay was previously described (Almac¸a et al., 2011).
The siRNAs (n = 17,840) targeting 6,409 different genes (Dataset S1) came
from three chemically synthesized libraries: the druggable (Ambion), the
kinome (Ambion), and the secretome library (Quiagen), as described (Simpson
et al., 2012). Additional reagents are in Supplemental Information.
Cell Culture
Human alveolar type II epithelial A549 cells (ATCC, Cat no. CCL-185) were
grown with or without dexamethasone (Dexa) as before, as well as WT- or
F508del-CFTR transduced A549 cells (Almac¸a et al., 2011). More cell culture
details are in Supplemental Information.
FMP/Amiloride Assay
The live-cell assay used to identify novel regulators of ENaC activity was per-
formed with the voltage-sensitive dye FMP and 30 mM Amil, as described
(Almac¸a et al., 2011) on A549 cells reverse-transfected for 48 hr with different
siRNAs (Erfle et al., 2007).
Automated Microscopy and High-Content siRNA Screening
Cells (150,000 cells)were plated in 1.5ml of culturemedium in siRNAprespot-
ted chambered slides. After 48 hr, cells were incubated for 10min with FMP as
described (Almac¸a et al., 2011). Cells on siRNA spots (1-384) were imagedwith
103 objective in Cy3 channel, the FMP solution was then automatically re-
placed by FMP/Amil; after 3 min, the same image acquisition routine started.
Secondary/Validation Screen and Hit Classification into ENaC
Pathways
For validation of primary screen hits, we used one to two additional indepen-
dent siRNAs targeting the top 456 hit genes (targeted by ENaC-inhibiting1398 Cell 154, 1390–1400, September 12, 2013 ª2013 Elsevier Inc.siRNAs) and performed the same FMP/Amil assay, image quantification, and
data analysis as for the primary screen, but with a different normalization
(see Supplemental Information). In order to classify the hits into three well-
known ENaC pathways, namely activation by proteolytic cleavage; Nedd4-
2-mediated internalization and degradation; and CFTR inhibition, parental
A549 cells were submitted to the different treatments detailed in Supplemental
Information.
Image Quantification and Primary Screen Data Analysis
For each acquired image the FMP-fluorescence intensity was measured
before and after Amil addition using a customized LabView-based program.
Complete details are in Supplemental Information.
Bioinformatic Analysis
The 1,657 primary screen hits (Dataset S1) were submitted to DAVID bio-
informatic analysis to identify the biological pathways (from the KEGG data-
base) most significantly overrepresented (Huang et al., 2009). For GO analysis
of validated genes, we used AmiGO (Carbon et al., 2009). Pathway analysis of
the validated screen hits was performed using ENSEMBL IDs (version 61) on
‘‘BioCompendium.’’ Bioinformatic analysis details are in Supplemental
Information.
Ussing Chamber Experiments
Non-CF and CF primary human bronchial epithelial cells, cultured as
described (Supplemental Information), polarized monolayers of H441 or M1
cells were grown on permeable supports (Millipore) for 10 days and then
mounted into a perfused micro-Ussing chamber with continuous (luminal
and basolateral) perfusion at 5–10 ml/min. Tracheal tissue was isolated from
mice. Experiments were carried out under open-circuit conditions at 37C. De-
tails are in Supplemental Information.
Target Validation by Double-Electrode Voltage-Clamp
Xenopus oocytes were injected with cRNA (10 ng, 47 nl double-distilled water)
encoding wild-type abg-ENaC subunits, a-ENaC with a C terminus truncation
(aH648X), and b-ENaC with N terminus deletion (bDN). Water injected oocytes
served as controls. Two to three days after injection, oocytes were impaled
with two electrodes as previously described (Kunzelmann et al., 2005).
Unpaired Student’s t test or ANOVA were used for statistical analysis, as indi-
cated, and p values lower than 0.05 were accepted as significant.
Plate Reader Experiments
To characterize the mechanism underlying ENaC regulation by DGK, the FMP/
Amil assay was performed on A549 cells using a plate reader (Novostar). A549
cells were transfected with either a scrambled or DGKi-siRNA for 72 hr and the
activity of several enzymes involved in phospholipid metabolism and signaling
wasmodulatedwith specific inhibitors and/or activators (for 2–5 hr)—PLC acti-
vator m3M3FBS at 25 mM, PLC inhibitor U73122 at 5 mM, PI3K inhibitor
LY294002 at 50 nM, PKC activator PMA at 100 nM, PKC inhibitor BIM at
50 nM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and five datasets and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.08.045.
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